• Home
  • Breast Cancer
  • Nephroblastoma
  • General Information
  • Links
  • About
  • Oncosimulator
  • Validation and Optimisation
  • Applications
  • GridR
  • Literature Mining
  • Clustering
  • General information
  • Links
  • Medical professionals
  • Researchers
  • Industry
  • Patients
  • Regulatory bodies
  • General public
  • Use an ACGT resource
  • Add my resource to ACGT
  • News list
  • Events
  • Newsletters
  • RSS feed
  • Public Deliverables
  • Dissemination materials
  • Publications
Member area
Print this page
You are here:HomeACGT for youGeneral publicCancer InformationNephroblastoma
banner
menu separation
  • general public
  • Cancer Information
  • Clinical Trials
  • Advocacy Groups
  • Services for public
  • In Silico Oncology
  • Knowledge Discovery tools
  • Kids
menu separation
  • Main menu
  • ACGT for you
  • General Information
  • User information
  • News
  • Consortium
  • Documents
  • Join us
  • Contact
  • FAQ
  •  

 

ACGT Newsletter

View Summer 2010 Issue

If you want to subscribe to the ACGT newsletter, please send us an email.

  • medical professionals
  • researchers
  • industry
  • patients
  • regulatory bodies
  • general public
  • Etiology
  • Prophylaxis
  • Screening
  • Clinical symptoms
  • Diagnostic procedures
  • Treatment
  • Prognosis

Nephroblastoma

 

Wilms tumor is the most common malignant renal tumor in children. Dramatic improvements in survival have occurred as the result of advances in anesthetic and surgical management, irradiation and chemotherapy. Today treatments are based on several multicenter trials and studies conducted by the SIOP (International Society of Paediatric Oncology) in Europe and COG (childrens Oncology Group, former: NWTS: National Wilms Tumour Study Group)in the USA. Main objectives of these trials and studies are to treat patients according to well-defined risk groups in order to achieve highest cure rates, to decrease the frequency and intensity of acute and late toxicity and to minimize the cost of therapy. In that way the SIOP trials and studies largely focus on the issue of preoperative therapy. The concept of neoadjuvant chemotherapy plays an important role in the treatment for most pediatric solid tumors today. The complete surgical removal of a shrunken tumor is facilitated, mutilation caused by surgical procedures is minimized or avoided and micrometastases, not visible at diagnosis, are treated as early as possible. Besides that, response to treatment can be measured individually by tumor volume reduction and / or percentage of therapy induced necrosis in the histological specimen. This might give an early individual prognostic parameter and can be used for further stratifying and more individualizing postoperative treatment as in other pediatric cancers. The International Society of Paediatric Oncology (SIOP) did enroll children with Wilms tumor into 7 studies up to now.

Design: HealthGrid
  • home
  • site map
  • disclaimer
  • contact